All Products

CJC-1295 no DAC

CAS 863288-34-0
$117 - $888

CJC-1295 no DAC

10mg per vial

CAS 863288-34-0

Available packs
2 vials
20mg
5 vials
50mg
10 vials
100mg
20 vials
200mg
In stock
Choose pack
Choose pack
Pack price
Selected pack
20mg pack
2 vials x 10mg · 20mg total · $5.85/mg
Pack price
$117
Quantity
1
$283 to free shipping.
Published certificate history is available below.

Research Use Only. Not for use in diagnostic tests.

Before ordering
  • Independent certificate details, manufacturer IDs, and batch IDs should be reviewed before purchase when available.
  • Order cancellations for full refunds are available before shipment; shipped orders cannot be cancelled or refunded.
  • For damaged or incorrect goods, photograph the outer packaging, inner packaging, and product labels, then email support within 48 hours of carrier delivery.

Swipe horizontally or use the left and right arrow keys to see all product details.

Scroll tables horizontally to view all columns.

CJC-1295 no DAC Kit

Save over 60%!
Swipe right to view full table →
Product Format
10mg vials
Vial Size
10mg
Vial Capacity
3 mL
Box Combinations
20mg, 50mg, 100mg, 200mg
Cost per milligram
$4.44 – $5.85
Multi-vial Purity
99.77%
Endotoxin Screening
PASSED
Heavy Metals Screening
PASSED
Purity Screening
PASSED
Doubly Validated
YES
Independently Tested
YES
Peptide Partners Manufacturer Id: WF03

Batch Id: CJ202606

 

Research Studies

(for educational purposes only)

Study 1: An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS

Authors: Gilles Coppieters, Koen Deventer, Michaël Polet, Peter Van Eenoo, Péter Judák Source: https://www.sciencedirect.com/science/article/abs/pii/S0731708522001479
Scientific Findings
This study presents a validated, antibody-free method for detecting GHRH analogues, including CJC-1295, in urine. The method utilizes ultrafiltration for sample preconcentration followed by nano-liquid chromatography-high-resolution mass spectrometry (nanoLC-HRMS/MS). This approach achieves low picogram-per-milliliter detection limits, offering a significant improvement over existing methods and enhancing the ability to detect misuse of these substances. The study highlights the method's potential for extension to other peptides and in vitro generated metabolites for which antibodies are not available.
Plain English Interpretation
Scientists have developed a new, highly sensitive test to find specific performance-enhancing drugs, like CJC-1295, in urine. Instead of using traditional antibody-based methods, which can be complex and time-consuming, this new technique uses a simple filtration process to concentrate the urine sample. Then, a very precise machine separates and identifies the drug molecules. This makes it possible to detect even tiny amounts of these substances, making it harder for athletes to cheat. The new test is also adaptable, meaning it can be used to find new or modified drugs that may appear in the future.  

Study 2: Advances in the detection of growth hormone releasing hormone synthetic analogs

Authors: Siham Memdouh, Ivana Gavrilović, Kelsey Ng, David Cowan, Vincenzo Abbate Source: https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/dta.3183
Scientific Findings
This study investigates the in vitro metabolism of four large GHRH synthetic analogs, including CJC-1295, in fortified human urine. The researchers identified nineteen major in vitro metabolites, which were then synthesized, purified, and characterized. A sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed for their detection, achieving limits of detection of 1 ng/mL or less. This method provides a new tool for anti-doping agencies to detect the misuse of these substances.
Plain English Interpretation
Scientists have developed a new laboratory method to detect the use of performance-enhancing drugs like CJC-1295. They studied how the drug breaks down in urine and identified 19 different breakdown products. Based on this, they created a highly sensitive test that can find even very small traces of the drug or its byproducts. This makes it much harder for athletes to cheat by using these banned substances without getting caught.  

Study 3: Human Growth Hormone-Releasing Factor (hGRF)1–29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog

Authors: Lucie Jetté, Roger Léger, Karen Thibaudeau, Corinne Benquet, Martin Robitaille, Isabelle Pellerin, Véronique Paradis, Pieter van Wyk, Khan Pham, Dominique P. Bridon Source: https://academic.oup.com/endo/article/146/7/3052/2500187
Scientific Findings
This study investigated the in vitro properties of three maleimido derivatives of human growth hormone-releasing factor (hGRF)1-29, including CJC-1295. The researchers found that when conjugated to human serum albumin, all three derivatives, including CJC-1295, exhibited enhanced stability against the enzyme dipeptidylpeptidase-IV (DPP-IV). Furthermore, in a growth hormone (GH) secretion assay using cultured rat anterior pituitary cells, the albumin-conjugated peptides were found to be bioactive, demonstrating their ability to stimulate GH release in a controlled, in vitro environment.
Plain English Interpretation
Scientists created a modified version of a substance that tells the body to release growth hormone, called CJC-1295. They tested this new version in the lab and found that it was more stable and resistant to being broken down by enzymes in the body. They also showed that it could still trigger the release of growth hormone from pituitary cells in a petri dish. This means that the modified substance is not only more durable but also remains effective at its job, which could lead to longer-lasting effects in the body.
Related products

Continue exploring the catalog